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FROM LAB TO CLINIC: THE PRACTICALITY OF USING EVENT RELATED 
POTENTIALS IN THE DIAGNOSIS OF ALZHEIMER’S DISEASE  
CHEONGMIN SUH 
ABSTRACT 
The main objective of this study was to investigate whether event related 
potentials (ERPs) can be used as a biomarker of disease severity staging in Alzheimer’s 
disease (AD) within a heterogeneous group of patients presenting to a memory disorders 
clinic for initial evaluation. Based on the known progression of AD pathology, we 
hypothesized ERP components would be abnormal, commensurate with disease severity 
in mild cognitive impairment (MCI) due to AD, mild, and moderate to severe dementia 
due to AD. ERP components were predicted based on the known sites of their neural 
generators. ERP peaks measured during an auditory oddball paradigm from twenty-two 
AD (n=9) and non-AD (n=13) patients were compared to their clinical outcomes using 
multivariate ANCOVA controlling for age with Bonferroni corrections. The predictive 
abilities of significant ERP components were examined using a binary logistic regression 
model. Significant between-group effects were found in N100 distractor amplitude, F(2, 
12) = 6.062, p = .015, ηp2 = .503. The results supported our hypothesis that N100 
amplitude would be increased in AD, suggesting that sensory gating may be more 
impaired in mild AD than in non-AD related cognitive impairment. 
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INTRODUCTION 
1.1 Alzheimer’s disease clinical features 
Alzheimer’s disease (AD) is a neurodegenerative disorder that begins insidiously 
with subtle changes, typically involving memory first, and then progressing to affect all 
cognitive domains. As this is a progressive disease, clinicians generally agree upon four 
broad stages of AD: mild cognitive impairment (MCI) due to AD, mild, moderate, and 
severe AD dementia (Budson and Solomon, 2016). Each stage is characterized by 
structural changes of the brain which result in deterioration of behavioral and cognitive 
function. Although impaired episodic memory is a hallmark of the disease, other 
cognitive domains deteriorate, including executive function (Tabert, Manly, Liu et al., 
2006; Price et al., 1993), followed by semantic memory (Price et al., 1993), personality, 
and visuospatial abilities. Eventually, the loss of all cognitive abilities during the end 
stage of AD results in the need for constant care (Budson & Solomon, 2016). The 
behavioral hallmarks of deteriorating cognitive impairment, observed at each stage of the 
disease are summarized in table 1. 
This project investigated the use of event related potentials (ERPs) as a candidate 
biomarker of disease severity staging in AD. ERPs are a cognitive measure that reflect 
synaptic changes in the brain and have been previously studied in the diagnosis of AD. 
The main objective of this study is to investigate whether ERPs can differentiate AD 
from non-AD related cognitive impairment, and can distinguish among the stages of 
clinical severity in AD. Given that AD typically progresses in a pathologically and 
neuropsychologically predictable manner, and that ERPs measure cognition based on the 
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physiological function of the brain, we anticipate that ERP measures will correlate with 
the degree of clinical severity. To our knowledge, this is the first study of its kind to 
implement ERPs as part of routine clinical workup in a memory disorders clinic, and to 
examine the sensitivity of ERPs to detect clinical severity.  
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Table 1. Behavioral and cognitive symptoms of MCI and stages of dementia due to 
AD.1 
MCI due to AD Mild dementia 
due to AD 
Moderate 
dementia due to 
AD 
Severe dementia 
due to AD 
Very mild 
cognitive decline 
Slight memory 
lapses 
Poor word-
finding 
Decline in ability 
to plan and 
organize 
Memory loss 
Confusion about 
location or 
familiar places 
Taking longer to 
accomplish 
normal daily tasks 
Trouble handling 
money and paying 
bills 
Poor judgment 
leading to bad 
decisions 
Loss of 
spontaneity and 
sense of initiative 
Mood and 
personality 
changes, 
increased anxiety 
Increasing memory 
loss 
Confusion 
Problems 
recognizing friends 
and family 
Poor judgment 
leading to bad 
decisions 
Difficulty 
organizing 
thoughts and 
thinking logically 
Inability to learn 
new things or to 
cope with new or 
unexpected 
situations 
Restlessness, 
agitation, anxiety, 
tearfulness, 
wandering 
Repetitive 
statements or 
movement 
Inability to 
recognize family or 
to communicate 
Lost sense of self 
Weight loss 
Groaning, 
moaning, grunting 
Increased sleeping 
Lack of bladder 
and bowel control 
Seizures, skin 
infections, 
difficulty 
swallowing 
Aspiration 
pneumonia 
Death 
                                                        
1 Adapted from Budson, A. E., & Solomon, P. R. (2016). Alzheimer’s Disease Dementia and Mild 
Cognitive Impairment due to Alzheimer’s Disease. Memory Loss: A Practical Guide for Clinicians. 
 4 
Hallucinations, 
delusions, 
suspiciousness, 
paranoia 
 
1.2 Neuropathology of AD 
 AD disrupts specific brain structures at each stage of the disease, as 
evidenced by post-mortem histopathological examination of AD brains. AD 
pathology typically starts in the entorhinal cortex of the medial temporal lobe (MTL) and 
then spreads quickly to the hippocampal formation, typically seen in MCI due to AD 
(Braak & Thal, 2011; Jack et al., 2000). In mild AD, AD pathology extends to the 
neocortical association areas which include the prefrontal, anterior superior temporal, and 
inferior parietal cortices, with association fibers in the cingulum bundle (Nieuwenhuys, 
2008). In moderate to severe stages of disease, AD pathology affects virtually all parts of 
the brain including primary sensory centers of the neocortex (Braak & Thal, 2011) (figure 
1).  
The histopathological changes in AD brains have been corroborated by further 
studies using neuroimaging methods. For example, Whitwell and colleagues (2001), 
using functional magnetic resonance imaging (fMRI), correlated patterns of brain atrophy 
with histological pattern of AD pathology. Murray and colleagues (2015) used Pittsburg-
compound B positron emission tomography (PiB-PET) to correlate PiB retention, which 
reflects burden of AD pathology, with AD clinical severity. 
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Figure 1. Spread of AD pathology in the brain at the different stages of Alzheimer’s 
disease.2 
Although the underlying pathophysiologic mechanism of AD is not yet fully 
understood, current research supporting the amyloid theory of disease propagation, 
suggests that the accumulation of tau neurofibrillary tangles (NFT) and amyloid beta 
(Aβ) results in synaptic loss and neurodegeneration (Raskin, Cummings, Hardy, Schuh & 
Dean, 2015; Selkoe & Hardy, 2016). Tau is a microtubule-associated protein that 
constitutes the neuronal cytoskeleton and provides structure to the cell. NFTs are 
abnormal, hyperphosphorylated tau proteins that remain after neuronal death. The 
presence of NFTs is more closely correlated with dementia severity in AD than is the 
accumulation of amyloid protein (Wilock & Esiri, 1982). Aβ is a 40- or 42-amino acid 
peptide segment of a larger, transmembrane glycoprotein known as the amyloid precursor 
protein. The accumulation of Aβ is thought to trigger subsequent pathophysiological 
damage which includes oxidative injury, activation of microglial and astrocytic 
inflammatory response, and hyperphosphorylation of tau protein, ultimately leading to 
                                                        
2 Adapted from Budson, A. E., & Solomon, P. R. (2016). Evaluating the behavioral and psychological 
symptoms of dementia. Memory Loss, Alzheimer's Disease, and Dementia: A Practical Guide for 
Clinicians. 2nd ed. Philadelphia, PA: Elsevier. 
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neurofibrillary tangles (for review, see Raskin et al, 2015). This cascade is thought to 
result in widespread synaptic dysfunction and neuronal loss that manifest in the clinical 
hallmarks of AD (Jack et al., 2013; Raskin et al., 2015; Selkoe & Hardy, 2016). 
Additionally, it is hypothesized that beta-amyloid and NFT accumulate in the most 
vulnerable regions of the brain first, then spread by way of direct neuronal connections 
from one affected region to the next (Thal, Rub, Orantes & Braak, 2002). 
NFT and Aβ pathology increases in both distribution and density as AD 
progresses, ultimately resulting in the gross anatomical changes and atrophy of specific 
brain structures seen in AD (Braak & Thal, 2011) (figure 2). In MCI due to AD, NFTs 
are predominantly observed in the MTL, specifically in the hippocampal formation, 
entorhinal and transentorhinal region, with involvement of subcortical structures such as 
the locus coeruleus (Braak, Alafuzoff, Arzberger, Kretschmar & Del, 2006). During this 
early disease stage, Aβ is often highly variable in spatial distribution throughout the 
brain. In some MCI patients, amyloid is entirely absent in the neocortex and in other 
cases, amyloid is present throughout both the neocortex and the medial temporal lobes 
(specifically, the CA1 field of the hippocampal formation and the entorhinal region), or 
even extends to include parts of the limbic lobe and subcortical structures such as the 
thalamus, hypothalamus and basal forebrain nuclei (Thal et al., 2002). 
In mild AD dementia, additional NFTs are observed in the neocortex of the 
fusiform and lingual gyri and the CA3 and CA4 regions of the hippocampus (Braak et al., 
2011). The locus coeruleus, the transentorhinal and entorhinal regions and CA1 and CA2 
of the hippocampus, all of which often contain NFTs beginning in MCI, show greater 
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density of tangles in mild AD. As mild AD worsens, NFT accumulation extends into the 
subiculum of the hippocampal formation and the neocortical association areas. As in MCI 
due to AD, Aβ may be observed again in spatially variable patterns of distribution during 
mild AD. In some cases of mild AD, amyloid is entirely absent in the neocortex and in 
other cases, plaques may be seen in the neocortex and extending into the subcortical 
structures including the central gray nucleus, superior colliculus, red nucleus, inferior 
olivary nucleus and the substantia nigra (Thal et al., 2002). 
During moderate to severe stages of AD, additional NFTs are found in the 
secondary and primary neocortical areas of the frontal, temporal and parietal lobes and 
extends into the peristriate and striate regions of the occipital cortex (Braak et al., 2011). 
Regions that had been affected by NFT accumulation in prior AD stages, now show 
increased density of NFTs. Aβ is observed in the regions mentioned in the MCI and mild 
AD stages, along with possible extension into the pons and its nuclei, central and dorsal 
raphe nuclei, locus coeruleus, parabrachial nuclei, dorsal tegmental nucleus, and the 
cerebellum (Thal et al., 2002). 
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Figure 2. Spread of NFT and Aβ pathology in the brain at different stages of AD.3 
Darker colors indicate greater density of pathology. Red arrows indicate additional Aβ 
deposits. 
                                                        
3 Adapted from Braak, H., Thal, D. R., Ghebremedhin, E., & Del Tredici, K. (2011). Stages of the 
Pathologic Process in Alzheimer Disease: Age Categories From 1 to 100 Years. Journal of Neuropathology 
& Experimental Neurology, 70(11), 960–969.  
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1.3 Neuroanatomical structures underlie specific cognitive domains 
Neuroanatomical structures affected by AD pathology can be ascribed to 
specific cognitive domains. The hippocampal formation and locus coeruleus, some of 
the earliest structures to be affected by AD pathology during MCI, are involved in either 
learning and memory or functions that subserve learning and memory (Braak et al., 
2011). The hippocampus itself is directly involved with learning and memory and is 
supported by connections both within and outside the MTL. Within the MTL, the 
hippocampus participates in the intrinsic hippocampal circuit with the entorhinal and 
transentorhinal regions, the hippocampal formation including the CA1 through CA4 
fields of Ammon’s horn, and the subiculum (Nieuwenhuys, 2008). The hippocampus is 
also an integral component of the Papez circuit, which has been found to be critical for 
episodic memory (Nieuwenhuys, 2008). Intrinsic and extrinsic connectivity of the 
hippocampus may allow for communication between memory-related structures within 
the hippocampus as they synthesize vast sensory information from the neocortex (Taylor 
& Probst, 2008). Lesions involving the hippocampus consistently result in severe 
episodic memory impairments (Scoville, 1968; Zola-Morgan, Squire & Amaral, 1986; 
Victor & Agamanolis, 1990), suggesting that integrity of the MTL is necessary for 
episodic memory function. 
The locus coeruleus (LC) is involved in attention and behavioral flexibility 
(Aston-Jones, Rajkowski & Cohen, 1999). The LC provides mainly norepinephrine (NE) 
                                                        
Adapted from Thal, D. R., Rüb, U., Orantes, M., & Braak, H. (2002). Phases of Aβ-deposition in the 
human brain and its relevance for the development of AD. Neurology, 58(12), 1791–800.  
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to cortical and subcortical structures throughout the brain, including the hippocampus 
(Aston-Jones et al., 1984), and provides particularly dense NE-mediated innervation to 
structures that are associated with attentional processing such as the parietal cortex, 
pulvinar nucleus of the thalamus, and the superior colliculus (Morrison & Foote, 1986). 
The LC-NE system acts to modulate the activity of target neurons (Servan-Schreiber, 
Printz & Cohen, 1990). Specifically, NE has been found to facilitate the functional 
integration of attentional systems of the brain (Coull, Buchel, Friston, & Frith, 1999), 
suggesting that the LC may influence cognitive domains such as memory, by modulating 
attention (Sara, 2009). NE was also found to have synergistic effects on long-term 
potentiation (Neuman & Harley, 1983), an electrophysiological marker of learning 
(Gazzaniga, 2014), suggesting that the LC-NE system is important for long-term memory 
consolidation (Sara, 2009). This is supported by studies showing lesions of the locus 
coeruleus results in impaired learning and memory (Anlezark, Crow & Greenway, 1973). 
During mild AD dementia, NFT and Aβ have typically expanded to include the 
frontal, temporal and parietal neocortical association areas involved in executive function 
with contributions to memory function (Braak et al., 2011). Executive function refers to 
many sub-functions involved in the planning, initiation and regulation of goal-directed 
behavior (Lezak, 1983), including attention, inhibition, and working memory. These 
subdomains also underlie and support complex cognitive domains including memory 
(Engle, 2002; McCabe et al., 2010). For example, frontal lobe function is often 
synonymous with executive function, participating in functions including registration, 
acquisition, or encoding of information (Wagner et al., 1998), free recall of information 
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without context or other cues (Petrides, 2002), and the recollection of the source of 
information (Johnson, Kounios & Nolde, 1997) as evidenced by various 
neuropsychological studies. Disruptions to frontal cortex circuitry lead to deficits in 
executive function as supported by lesion studies (examples: McAndrews & Milner, 
1991; Milner, Petrides & Smith, 1984). Neocortical association cortices are thought to 
play a role in executive function by consolidating sensory input from primary sensory 
cortices before projecting these inputs to subcortical structures (Pandya & Yeterian, 
1985). Neocortical connections to the hippocampal formation via cingulum bundle also 
illustrate their contribution to memory (Suzuki & Amaral, 1994; Lavenex & Amaral, 
2000). 
The neocortical association areas are also involved in semantic memory. Semantic 
memory refers to stored information of concepts and factual knowledge that cannot be 
pinpointed to a specific time or event, such as knowing the color of the sky or that tigers 
have stripes (Budson, 2005). Semantic memory is believed to be diffusely stored in the 
brain (Hodges & Patterson, 1995), including regions outside of the language network, 
traditionally thought to be composed of Broca’s area on the inferior frontal gyrus, 
Wernicke’s area in the superior temporal gyrus, and the temporo-parietal junction, 
typically lateralized to the left hemisphere in right-handed individuals (Mesulam, 2001; 
Nieuwenhuys, 2008). Semantic memory may also be stored in higher-order association 
areas in the left hemisphere, likely providing intermediary support to the primary 
language regions (Demasio, 1996; Mesulam, 2016). The view that semantic memory is 
diffusely stored throughout the brain is supported by the wide projections of the language 
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network and higher-order association areas throughout the brain (Mesulam, 2001), and by 
neuroimaging evidence. In healthy individuals, auditory language comprehension has 
been associated with activity in the left superior, middle, and inferior temporal gyri, left 
inferior parietal, and left superior prefrontal regions (Demonet et al., 1992). Significant 
lesions to the language-related regions or circuitry are correlated with prominent 
language deficits as seen in patients with primary progressive aphasia, whose anomia, 
word-finding, and comprehension difficulties may be attributed to the disruption of the 
network involved in semantic processing, retrieval, and word usage (Mesulam, 2001).  
During moderate to severe AD, the occipital lobes are one of the few remaining 
regions to be invaded by NFT and Aβ deposition (Braak et al., 2011), which accounts for 
the relatively late disturbance of visuospatial abilities in AD patients (Budson & 
Solomon, 2016). The occipital lobes, like other neocortical regions, are connected to both 
cortical and subcortical regions. For example, both the peristriate and striate regions of 
the occipital lobes are involved in the visual processing stream via the inferior 
longitudinal fascicle (Nieuwenhuys, 2008). Lesions in the occipital lobes have been 
linked to impairments in visuospatial functions, as seen in rare cases of AD, posterior 
cortical atrophy (PCA) associated with AD (Benson, Davis & Snyder, 1988). In these 
unusual AD variant, the visual system is involved first, even in early disease stages and 
PCA patients typically present with higher-order visual dysfunction involving 
disturbances of visuospatial, visuoperceptual, visuomotor and visual information 
processing (for review, see Cronin-Golomb & Amick, 2001). Visual disturbances are 
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thought to arise due to the disruption in the interaction between cortical information 
processing systems (Morrison, Hof & Bouras, 1991). 
1.4 Neuropsychological tests to assess cognitive capacities 
 The progression of cognitive impairment observed throughout the stages of AD 
can be measured using specific neuropsychological tests, which target cognitive domains. 
Neuropsychological tests provide performance-based measurements of various cognitive 
domains that can be used in normative comparison across individuals of various ages, 
educational levels, and backgrounds (Harvey, 2012). According to the Alzheimer’s 
Disease Centers (ADC) program of the National Institute of Aging (NIA), the domains 
that show the greatest deficits in the neuropsychological profile of AD patients are: 
attention, speed of processing, executive function, episodic memory and language 
(Weintraub et al., 2009). 
In MCI due to AD, early changes in the hippocampus result in subtle changes in 
episodic memory (Perry & Hodges, 1999; Chen et al., 2001). The hippocampus is one of 
the major anatomical structures thought to be involved in episodic memory, along with 
the surrounding structures of the MTL, basal forebrain, retrosplenial cortex, 
presubiculum, subiculum, anterior thalamic nucleus, mammillary body, and the prefrontal 
cortex (Mesulam, 2000). Episodic memory is commonly assessed using the Consortium 
to Establish a Registry for Alzheimer’s disease (CERAD) word list test (Morris et al., 
1989). One study found that the summed score across three trials of immediate recall in 
the CERAD word list learning task was highly sensitive to the presence of MCI due to 
AD (Karrasch, Sinerva, Grönholm, Rinne & Laine, 2005). The Trails making tests 
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(TMT) A and B are tests of executive function. TMT A measures processing speed and 
attention while TMT B measures cognitive flexibility and set shifting (Reitan, 1958). 
Performance on TMT B has been found to significantly differ between individuals with 
MCI due to AD and healthy controls (Salmon et al., 2002). Working memory has also 
been shown to be impaired in MCI due to AD patients (Baddeley et al., 1991). 
Impairments observed in mild AD dementia result from alterations in structures of 
the neocortical association areas, extending to include difficulties with language, in 
addition to worsening memory and executive function (Price et al., 1993). Mild AD 
dementia patients perform poorly on CERAD delayed recall, in addition to poor encoding 
on trials one through three of the CERAD word list learning task (Welsh et al., 1991; 
Welsh-Bohmer & Mohs, 1997). Mild AD dementia patients also exhibit a rapid rate of 
forgetting, or the inability to recognize previously seen words within a short period of 
time (Budson and Solomon, 2016). The presence of a rapid rate of forgetting is highly 
sensitive to the diagnosis of AD (Flicker, Bartus, Crook & Ferris, 1984; Butters et al., 
1988; Knopman & Rybert 1989; Welsh et al., 1991; Tröster et al., 1993) and suggests 
that AD affects patients’ ability to consolidate information as opposed to the retrieval of 
information (Delis et al., 1991; Weintraub et al., 2012). In the mild AD dementia stage, 
simple attention as measured by TMT A performance is typically intact, whereas 
performance on TMT B is often significantly impaired (LaFleche & Albert, 1995). 
Deficits in language and semantic knowledge are commonly measured by the Boston 
Naming Test (BNT) (Mack, Freed, Williams, & Henderson, 1992) and verbal fluency 
tasks (Morris et al., 1989). The BNT is a confrontation naming task and poor 
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performance reflects the loss of semantic knowledge for particular items (Weintraub et 
al., 2012). Verbal fluency can be assessed both semantically, where subjects must name 
as many items that fit within a category in one minute, and phonemically where subjects 
must name as many items that start with a specific letter as possible in one minute. Mild 
AD dementia patients typically perform worse on the category fluency task compared to 
the letter fluency task (Butters, Granholm, Salmon, Grant & Wolfe, 1987; Monsch et al., 
1992; Henry, Crawford, & Phillips, 2004). This pattern of verbal fluency performance 
suggests that AD affects the ability to organize semantic memories, which supports 
language, rather than retrieval or access of semantic knowledge (Weintraub et al., 2012). 
By the time a patient reaches the moderate to severe stages of AD dementia, 
neuropathological changes extend to include the occipital lobe and primary sensory 
cortices which result in the alterations in nearly all cognitive domains (Price et al., 1993). 
During moderate AD, cognitive impairment is present in nearly all aspects of executive 
function, including working memory and sustained attention (Baddeley et al., 1991). 
Both TMT A and TMT B time to completion deteriorate significantly in comparison to 
healthy controls (Greenlief, Margolis, & Erker, 1985). Additionally, significant 
differences in visuospatial abilities (i.e., by constructional praxis test) are observed in 
moderate AD (Yuspeh, Vanderploeg, & Kershaw, 1998). As noted by Weinberg and 
colleagues (2012), the distinction of particularly affected cognitive domains seen early in 
the course of AD (dark-shaded bars) become difficult to observe during later disease 
stages (light-shaded bars) (figure 3). By the time a patient reaches severe AD dementia, 
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he is oriented only to himself and judgment or reasoning may not be possible (Budson & 
Solomon, 2016). 
Neuropsychological tests are considered to be objective measures of cognitive 
processes. However, the tests often rely upon strongly correlated cognitive components 
across multiple domains and the specific properties of the tests are often not fully 
understood (Arnaiz & Almkvist, 2003). For example, attention is commonly required 
across multiple tests since it aids complex cognitive processes such as memory (Engle, 
2002; McCabe et al., 2010); thus, attentional deficits may impair performance on tests of 
both attention and memory. Furthermore, even when attentional deficits are found, the 
subtypes of attention are often not easily teased apart by NP tests (Perry & Hodges, 
1999). Thus, neuropsychological tests are useful clinically in the staging of AD patients 
but also contain intrinsic limitations.   
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Figure 3. Neuropsychological profile of AD dementia in early versus late stages.4 
Dark bars indicate early AD stages. Grey bars indicate late AD stages. 
 
1.5 Electroencephalogram and Event Related Potentials 
 Electroencephalograms (EEG) and event related potentials (ERPs) are additional 
methods of measuring cognitive function generated by specific neural structures. EEGs 
are a non-invasive neurophysiologic tool that records the global electrical activity of the 
brain using electrodes placed on the scalp surface (for review, see Kirschstein & Kohling, 
2009). EEGs reflect synaptic activity, specifically, the summation of excitatory 
postsynaptic potentials (EPSPs) and inhibitory postsynaptic potentials (IPSPs). EPSPs 
and IPSPs in a neuron summate to produce a dipole, or a difference in charge in a neuron. 
When individual dipoles are produced by many neurons oriented in a similar fashion, a 
                                                        
4 Adapted from Weintraub, S., Wicklund, A. H., & Salmon, D. P. (2012). The neuropsychological profile of 
Alzheimer disease. Cold Spring Harbor perspectives in medicine, 2(4), a006171. 
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net dipole is produced that is strong enough to be conducted through the scalp (Jackson & 
Bolger, 2014). Ultimately, EEG measures the net dipole of populations of similarly 
oriented neurons. EEGs provide a physiological measure of cognitive processes and 
synaptic health, and thus signals vary with cognitive state (Berger, 1969). 
ERPs are time-locked, quantitative EEG recordings that measure cognitive 
responses to specific stimuli. They are recorded as a subject completes a task-related 
paradigm which involves a series of discrete auditory or visual stimuli. Averaged ERP 
signals are composed of multiple ERP components, or peaks, that are thought to reflect 
specific cognitive processes. Whereas EEGs reflect the global electrical activity of the 
brain, ERPs record changes in brain activity in response to particular tasks. The auditory-
oddball ERP paradigm exposes subjects to a series of auditory stimuli, and measures the 
resultant ERP peaks. P50, N100 and P200 are early sensory responses that are thought to 
act as a cognitive filter in a mechanism called sensory gating (Golob, Irimajiri & Starr, 
2007; Lijffijt, Lane et al., 2009). Sensory gating is a protective mechanism that filters 
irrelevant sensory information, therefore ultimately modulating, higher-order cognitive 
processing (Lijffijt, Moeller et al., 2009). A lack of attenuation in sensory gating 
components in response to a repeated and expected auditory stimulus indicates deficits in 
sensory processing which may affect higher cognitive processes (Lijffijt, Moeller et al., 
2009; Thomas et al., 2010). 
The prefrontal cortex (PFC) is thought to be a major generator of P50. Lesion 
studies of unilateral PFC damage show increased early auditory components (Knight, 
Staines, Swick, & Chao, 1989). The increased P50 amplitudes seen in PFC lesion patients 
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are attributed to impaired sensory gating mechanisms (Knigh, Scabini, Woods & 
Clayworth, 1989; Green et al., 2015). 
The auditory cortex of the temporal lobe is thought to be a major generator of 
N100 (Rogers, Papanicolaou, Baumann, Saydjari, & Eisenberg, 1990) with involvement 
of the PFC (Knight, Staines et al., 1999). This is supported by the observation of the 
magnetic equivalent of N100, called the M100, originating in the temporal lobe 
(Woldorff et al., 1993). N100 peaks were significantly reduced in patients with PFC 
lesions (Chao & Knight, 1998; Knight et al., 1999). 
Strong evidence for a major generator of P200 has yet to emerge; however, the 
anterior region of the temporal lobes and the frontal lobes are thought to be involved in 
P200 generation (Rogers et al., 1990). Unilateral lesions of the temporal lobe involving 
the anterior regions of the superior temporal gyrus resulted in moderately diminished 
P200 amplitude (Knight, Scabini, Woods & Clayworth, 1988). This is corroborated by 
statistically significant observations of M200 localized anterior to the auditory cortex 
(Hari et al., 1987). Frontal lobe is thought to modulate P200 generation (Knight et al., 
1988) since frontal lobe atrophy has been highly correlated with P200 amplitude in 
attentive conditions (McCarley et al., 1989). 
N200 and P300 are cognitive ERP components which reflect mechanisms of 
higher cognitive functioning and occur after approximately 200 milliseconds post-
stimulus onset are indicative of higher-order cognitive processing such as attention, 
memory, and executive function (Olichney, Yang, Taylor, & Kutas, 2011; Yurgil & 
Golob, 2013). These include N200 and P300 and are called cognitive components. The 
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N200 is thought to represent early target discrimination in relation to cognitive control 
which is defined as “the ability to orchestrate thought and action in accordance with 
internal goals” (Miller & Cohen, 2001). The P300 is thought to reflect an update to the 
working memory and stimulus categorization (Polich, 2007; Olichney et al. 2011) and 
can be broken down into the subcomponents:  P3a and P3b (Squires, Squires, & Hillyard, 
1975). 
The cingulate cortex and the temporal lobe are thought to be the major neural 
generator of the N200. ERP-fMRI evidence localizes N200 to the anterior region of the 
mid-cingulate cortex (Huster, Westerhausen, Pantev, & Konrad, 2010) and in the middle 
and superior temporal gyri (Kiehl, Laurens, Duty, Forster, & Liddle, 2001). This is 
further corroborated by neuropsychological findings that associate N200 peak with 
inhibition and conflict monitoring (Huster et al., 2010; Botvinick, Cohen, & Carter, 
2004), processes which have been linked in part to the cingulate cortex (Botvinick et al., 
2004). 
Neocortical association cortices are thought to be the neural generators of the 
P300 peak. The P300 signal can be further divided into P3a and P3b peaks which likely 
have different neural generators (Polich, 2007). Intracerebral EEG has been used to 
localize P3a generators in the frontal and temporal lobes, specifically in the dorsolateral 
prefrontal cortex, supramarginal gyrus, and the cingulate gyrus (Halgren, Marinkovic, & 
Chauvel, 1998). The same study localized P3b generators to frontal, temporal and parietal 
lobes, specifically the ventrolateral prefrontal cortex, superior temporal sulcus, posterior 
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superior parietal lobe, and the medial temporal lobe including the hippocampal and 
perirhinal cortices.  
The localizations of P3a and P3b are further supported by lesion and 
neuroimaging studies. Lesion studies show that patients with focal hippocampal lesions 
produced decreased P3a amplitude but normal P3b components (Knight, 1996). Patients 
with frontal lobe lesions also demonstrated reduced P3a amplitudes (Knight, 1984), 
supporting the involvement of the dorsolateral prefrontal cortex in P3a generation. 
Overall, the P300 is generated by a distributed network of the neocortex that suggests that 
the P300 is involved in a heterogeneous set of cognitive processes (Olichney et al., 2011). 
EEGs and ERPs possess high temporal resolution at millisecond intervals, but 
lack spatial resolution (Jackson & Bolger, 2014). Sources other than the major neural 
generator of an ERP peak may contribute to the measured signal at the scalp (Jackson & 
Bolger, 2014). However, ERP components with known neural generators provide 
valuable link between neuroanatomy and cognitive processes. Given that the pathology at 
each stage of AD has been well-characterized by histopathological studies, changes in 
ERPs generated by affected brain regions at each stage of AD can be predicted. The 
findings may have clinical diagnostic value in the discrimination of AD patients at 
different levels of clinical severity from non-AD related cognitive impairments. 
1.6 Hypotheses 
We hypothesized that AD patients would have abnormal ERP amplitudes 
and latencies for specific peaks versus those values seen in age-matched healthy 
controls, commensurate with the severity of their AD.  
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In MCI due to AD, we hypothesized that P3b would be decreased in amplitude 
given that the MTL is thought to be one of its neural generators, and the MTL is often 
one of the earliest structures to be affected by AD pathology (Braak & Thal, 2011).  
In mild AD dementia, we hypothesized that P50, N100, P200, N200, and P3a in 
addition to P3b would be observed in abnormal ranges given that wide-spread neocortical 
association areas involving the frontal, temporal and parietal lobes are impaired at this 
stage of AD. The neural generator of P50 is in the frontal lobe; N200 in the temporal 
lobe; P200 and P3a in the frontal and temporal lobes; and P3b in frontal, temporal and 
parietal lobes. We hypothesized that the N100 would be abnormal because it is highly 
modulated by neural generators in the frontal lobes (Knight, Staines et al., 1999). 
Additionally, we anticipated that P50, N100 and P200 would increase in amplitude since 
they are thought to reflect primarily early sensory responses, rather than cognitive 
processes, and are thus susceptible to potentially impaired sensory gating in mild AD. We 
expected P3b to be further decreased in amplitude and increased in latency than the 
values seen in MCI due to AD given that AD pathology increases in severity in the 
hippocampus with progression of disease stage. 
Finally, in moderate to severe AD, we hypothesized that all ERP components 
above, P50, N100, P200, N200, P3b, and P3a will show further deviation from normal 
ranges given that AD pathology increases in density with the progression of disease 
stage. 
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METHODS 
Ethics Approval  
Initial human research study approval was granted by the Department of Veterans 
Affairs, VA Boston Healthcare System Institutional Review Board from January 25, 
2016 to January 24, 2017 under the protocol #2979. A renewal was requested, and 
approved effective until January 24, 2018. Recruitment of participants officially began in 
July 2016.   
Participants and Initial Screening 
 Study participants were recruited from the Memory Disorders Clinic at the VA 
Boston Healthcare System in Boston, Massachusetts. At the time of recruitment, 
participants were all new patients to the Memory Disorders clinic, aged between 50 and 
100 years old, and scored 10 or above on the Montreal Cognitive Assessment (MoCA) 
(Nasreddine et al., 2005). All patients were either self-referred for memory complaints or 
referred to the clinic by their primary care physicians for memory problems. As a 
prospective study, the goal of the experimental design was to recruit participants 
indiscriminately to explore the extent to which ERPs could be used in a memory clinic 
population. Participants were not excluded based on comorbid conditions or 
pharmacological intake, so as to generate a representative sample of patients visiting a 
memory disorders clinic. 
Subjects who agreed to participate scheduled a follow-up appointment with a 
research assistant within six-weeks of the first clinic visit. Each follow-up appointment 
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consisted of two-hours of testing including a standard neuropsychological battery (NP) 
and EEG. All patients gave their informed consent prior to EEG testing. Patients returned 
to the clinic between three to six months after the initial visit to receive a clinical 
diagnosis from a behavioral neurologist. 
Between July and December 2016, a total of 59 patients consented. Of those, 20 
were excluded, 13 of which did not meet the post-EEG inclusion criteria due to low 
button press accuracy and/or poor audiometry testing, details of which are described 
below, and six of which discontinued testing due to various reasons. One other subject 
completed testing but was not included due to issues with ERP recording. Of the 39 
participants who did meet inclusion criteria, only 22 had returned to the clinic to receive a 
diagnosis by the time of this writing. Although gender was not a screening criteria, the 
majority of the patients seen in the memory disorders clinic were males given the veteran 
population. Hence, a total of 22 male subjects were included in the data analysis of 
clinical diagnosis. The demographic information including MoCA scores used for 
screening is summarized in table 2. Age was the only significantly different factor 
between non-AD and AD groups (p = .027). Statistical comparison of the global 
cognitive assessment showed that MoCA and MMSE scores were not significantly 
different between groups.  
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Table 2. Demographic data. 
Characteristics Non-AD (n = 13) AD (n = 9) 
Age 72.1  ± 2.09 
78.1 ± 1.77* 
(P = .027) 
Education (years) 15 ± 1.01 13.7 ± 0.62 
MoCA 22.5 ± 1.16 19.4 ± 1.03 
MMSE 27.2 ± 0.60 24.2 ± 1.46 
Note: Data are represented as mean ± SEM. *P  < .05 compared with non-AD. 
Abbreviations: AD, Alzheimer’s disease, any stage; MoCA, Montreal cognitive 
assessment; MMSE, mini-mental state examination; ERP, event related potentials; 
SEM, standard error of the mean 
 
Inclusion Criteria 
After EEG testing, audiometry and button press accuracy (BPA) results for each 
participant were further examined using the Cognision™ software to determine cutoffs 
for inclusion in data analysis. Audiometry scores were broken down into hearing 
thresholds at 1000 Hz and 2000 Hz for each ear. These two frequencies corresponded 
respectively to the standard and target stimuli used in the auditory oddball paradigm. 
Patients whose minimum hearing threshold was 80dB in one frequency in both ears or in 
more than one frequency in either ear were excluded from analysis. Patients whose BPA 
were below 35% accuracy on the 400-tone auditory oddball task were also excluded from 
analysis to preserve reliability of the averaged ERP signals.  
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Study Design: EEG 
 The EEG equipment was donated by Neuronetrix, but the study was not otherwise 
funded or sponsored by Neuronetrix. A seven-electrode Cognision™ headset was used to 
collect EEG data. Cognision™ has been FDA-approved for use in the identification and 
diagnosis of Alzheimer’s disease. EEG activity was recorded from sites Fz, F3, F4, Cz, 
C3, C4, Pz, P3, and P4 sites on the 10/20 international system (Klem, Luders, Jasper, & 
Elger, 1958) with reference electrodes on each mastoid process (M1, M2) and one ground 
electrode on the frontal bone (Fpz) (Figure 4). 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Electrode placement sites for Cognision™ 
 
The procedure was split into four parts: an audiometry test, a forty stimuli 
auditory-oddball practice test, a four-hundred stimuli auditory-oddball full test which 
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spanned approximately thirty-minutes, and a three-minute resting state EEG recording. 
Participants first completed an audiometry test, the results of which were automatically 
used by the Cognision™ software to adjust the tone volume to account for any hearing 
loss. Participants with audiometry results exceeding 80 dB in either ear did not proceed 
with further testing. 
Next, participants underwent an auditory-oddball paradigm. Stimuli consisted of a 
1000 Hz standard tone, 2000 Hz target tone, and a white noise distractor, appearing with 
75%, 15% and 10% chance respectively in pseudorandom order. The target and distractor 
tones were never presented sequentially. The practice session consisted of a forty-trials 
where a mixture of frequent standard and infrequent target tones were presented through 
sound-isolating earbuds. Participants were instructed to press a button on the handheld set 
using their dominant hand each time they heard the higher pitched tone. Participants were 
corrected during the practice test for errors, and were allowed to take the practice up to 
three times. EEGs from the practice session were recorded but not used for analysis. If a 
participant completed the practice session with at least 80% success, he or she moved on 
to the full task consisting of four-hundred tones that contained a mixture of frequent 
standard and infrequent target and distractor tones with the same probability of 
appearance mentioned above. Within the four-hundred total tones of the full length test, 
there were three-hundred standard, sixty target, and thirty distractor tones appearing in 
pseudorandom order. Participants were instructed to press the button only if they heard 
the same high-pitched target tone that was presented in the practice session, but not for 
other tones, and to press the button as soon as they heard the target tone. If participants 
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incorrectly pressed the button for the distractor tone, they were reminded to press the 
button only for the same tone they had heard in the practice. No other corrections were 
given during the real test. Finally, participants were instructed to sit comfortably with 
their eyes closed for three-minutes while their resting state EEG was recorded. All EEG 
testing took place in a quiet room behind closed doors to minimize distractions. 
All preprocessing of the EEG data was completed by the Cognision™ software. A 
single trial (epoch) was defined from approximately -240 ms pre-stimulus to 1000 ms 
post-stimulus onset. Reaction time (RT) was measured from the onset of stimulus at 0 ms 
to the time of button press. Peak amplitude was measured in microvolts (µV) between 
maximum peak amplitude and mean pre-stimulus baseline. Latency was measured in 
milliseconds between maximum amplitude and stimulus onset. The Cognision™ system 
software automatically extracted and defined all ERP components. The EEG signal was 
baseline corrected using the pre-stimulus period. Only the standard tones immediately 
preceding the target or distractor tones were averaged. Any recordings that exceeded two 
times the root mean square value were rejected from averaging, as were any false alarms. 
Only ERPs that averaged more than twenty times after preprocessing (equivalent to BPA 
of 35%) were included in analysis. The results of the EEGs were automatically generated 
in a report by the software. 
A neurologist categorized each subject based on whether the ERP results seemed 
consistent with MCI due to AD, mild AD, moderate AD, non-AD or an indeterminate 
diagnosis given the ranges of ERP values that reflected healthy versus mild AD adults. 
Since no cutoffs are available that delineate the clinical stages of AD based solely on 
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ERPs, the ERP evaluations reflect clinical judgement based on the range of healthy 
versus mild AD conditions by taking into consideration the number of ERP abnormalities 
and the magnitude of deviation from normal ERP ranges. While evaluating the ERPs, the 
neurologist was blinded to the patient history and all other clinical measures typically 
used to diagnose AD. All ERP reports were identified by study codes such that the results 
could not be traced back to the identity of the participant. The neurologist used an ERP 
rating form (appendix A) to aid evaluations. The purpose of the ERP rating form was 
two-fold. First, it served as a reference for the ranges of normal versus abnormal ERP 
measurements using cutoffs used by Cecchi and colleagues (2015). Secondly, the rating 
form allowed for clear notation of abnormal components to facilitate quick identification 
of abnormal ERPs. Raters evaluated seventeen different measures in all, consisting of 
behavioral measures, peak alpha frequency, and ERP amplitudes and latencies. All 
abnormal ranges in the mild AD range as previously identified by Cecchi and colleagues 
(2015), were noted in red on the ERP rating form. Of these, the abnormal measures 
related to the cognitive components (N200, P3a, P3b) were bolded to indicate greater 
diagnostic weight relative to the sensory components. The numbers of abnormal 
indicators in red and abnormal significant indicators in bold were considered by the raters 
as they categorized each subject as MCI due to AD, mild AD, moderate AD or non-AD 
using ERP results alone, blinded to the patient history and all other clinical measures 
typically used to diagnose AD. 
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Clinical Diagnosis 
A neurologist determined the clinical diagnosis for each participant independent 
of the ERP data at the participant’s second appointment at the memory disorders clinic. 
Per current practice, neurologists take into consideration a patient’s medical history, 
neurological examination, neuroimaging results and the results of the neuropsychological 
battery to assess whether the memory problems are due to AD or non-AD etiologies. 
Clinically, the differential of AD is further defined as mild, moderate or severe according 
to the results of a neuropsychological (NP) battery as well as history of functional 
decline. NP testing provides objective measures of cognitive functions through the 
assessment of several cognitive domains. All participants completed a NP battery 
consisting of the Mini-Mental State Examination (MMSE) (Folstein, Folstein, & 
McHugh, 1975), Consortium to Establish a Registry for Alzheimer’s disease (CERAD) 
word list test (Morris et al., 1989), trail making tests (TMT) A and B (Reitan, 1958), 
letter and category word fluency (Morris et al., 1989), and the Boston Naming Test-Short 
Form (BNT) (Mack, Freed, Williams, & Henderson, 1992; Goodglass, Kaplan, & 
Weintraub, 1983). Please refer to the introduction for a discussion on the relevance of 
each test. 
The Montreal cognitive assessment (MoCA) and the mini-mental state 
examination (MMSE) are brief screening tools that provide a global assessment of a 
patient’s cognition. These tests were designed to assess a patient’s orientation, 
registration, memory, attention, language, and constructional praxis in ten minutes for use 
in practical clinic settings. Both tests are scored out of 30 points where 30 is the perfect 
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score. At a normal cutoff score of 26, the MoCA has high specificity for differentiating 
healthy individuals from mild stages of dementia (Nasreddine et al., 2005). The MMSE 
has greater sensitivity and specificity in differentiating between the later stages of the 
disease (Nasreddine et al., 2005). No single cutoff score determines the severity of 
cognitive impairment beyond the MoCA cutoff of 26. Therefore, clinical diagnosis must 
include the consideration of other aspects of a patient’s presentation using clinical 
judgment (Nasreddine et al., 2005). A range of cutoff scores generally used by clinicians 
is listed in the table 3. Clinically, it has been observed that AD patients typically decline 
by 2-3 points in these scores each year (Budson & Solomon, 2016). The MoCA was 
administered to all new patients as part of a routine clinic procedure during their first 
visit. The MMSE and other NP exams were administered at a follow-up appointment as 
part of standard clinical care.  
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Table 3. Cutoff scores on global cognitive screening tests for the staging of AD 
(Nasreddine et al., 2005; Budson & Solomon, 2016) 
Disease Stage MoCA MMSE 
Unimpaired 26-30 27-30 
Mild cognitive impairment 19-25 24-27 
Mild AD 11-21 16-26 
Moderate to severe AD <11 <16 
 
 
Missing Data 
Nineteen cases noted missing values in the measurement for one or more of the 
following ERPs: P200 standard latency, P200 target amplitude and latency, and N200 
target amplitude and latency. Despite the missing amplitude and latencies, the average 
amplitudes were recorded for all of these cases. Additionally, there was one case in which 
the system recorded “n/a” across all distractor amplitude, latency and average amplitude 
and latency. Since the system automatically rejects trials in which a button press error 
occurred, this was most likely due to the participant pressing the button for all distractor 
tones during the testing session. Besides this single case, none of the subjects who were 
missing these measurements were excluded from analysis, in order to retain adequate 
sample size.  
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Statistical Analysis 
IBM SPSS Statistics, Version 20.0 (IBM Corps, Armonk, NY) was used to 
conduct all data analyses. Any cases that had missing values were excluded from 
analyses on a case by case basis. Given the prospective nature of the study design, there 
was no way to ensure an equal sample size for each of clinical diagnosis. The sample 
sizes of each diagnostic group was as follows: 1 MCI due to AD, 8 mild AD, 0 moderate 
AD and 13 non-AD cases. Given the limited number of participants, all AD cases were 
binned into a single group of n=9. The distribution of the blinded ERP diagnosis of the 
same cases was as follows: 9 MCI due to AD, 9 mild AD, 0 moderate AD and 4 non-AD 
cases. 
Group comparisons were conducted using the Mann-Whitney U and Krusker-
Wallace tests for non-parametric data in age, education, MoCA and MMSE scores (table 
4). Age was significantly different between non-AD and AD groups (U=91.5, p=.025) 
and was used as a covariate in all statistical comparisons where data correlated with age. 
P values <.05 were considered significant. A Bonferroni correction was applied to all 
multiple comparisons to control for type I errors and the adjusted P values were reported. 
A multivariate ANCOVA was used to determine group differences in the z-scores 
of ERP measures between clinically diagnosed AD and non-AD groups. Confidence 
interval was adjusted by Bonferroni method and significant effects of BPA and any 
significant ERP measurements from multivariate ANCOVA were further examined by 
bias corrected accelerated (BCa) bootstraps to obtain robust results. The predictive 
abilities of significant ERP measurements were examined by binary logistic regression 
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where age was entered as step one and ERP measurements were placed as forced entry 
inputs with BCa bootstraps. 
  
 35 
RESULTS 
Table 4. Group comparisons of ERP measures.  
ERP Measure Non-AD (n = 13) AD (n = 6) 
BPA (%) 93.7 ± 2.7 
78.14 ± 7.7 * 
(P = .023) 
FA (%) 2.73 ± 1.1 4.77 ± 1.2 
Mean RT (ms) 514.80 ± 41.0 516.44 ± 38.9 
N100std amp (µV) -5.57 ± 0.6 -7.74 ± 1.3 
P200std amp (µV) 4.91 ± 0.9 4.22 ± 0.7 
N100tar amp (µV) -4.91 ± 0.6 -5.61 ± 1.4 
N200tar amp (µV) -2.37 ± 1.0 -1.03 ± 1.4 
N200tar lat (ms) 259.23 ± 10.2 262.23 ± 14.1 
P3btar amp (µV) 4.16 ± 1.1 4.29 ± 1.3 
P3btar lat (ms) 392.05 ± 20.5 413.48 ± 22.5 
P50dis lat (ms) 44.09 ± 3.1 36.69 ± 5.3 
N100dis amp (µV) -3.40 ± 1.4 
-7.80 ± 1.6 * 
(P = .015) 
P3adis amp (µV) 7.05 ± 1.0 7.50 ± 2.1 
Note: Data are represented as mean ± SEM. *P < .05 compared with non-AD.  
Abbreviations: std, standard; amp, amplitude; lat, latency; SEM, standard error of 
the mean 
 
To examine the correspondence of individual ERP measures and clinical 
diagnosis, a multivariate ANCOVA [between-subjects factor: clinical diagnosis (non-AD, 
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AD); covariate: age] was conducted. The test revealed significant effects of BPA, F(2, 
12) = 5.228, p = .023, ηp2 = .466, and N100 distractor amplitude, F(2, 12) = 6.062, p = 
.015, ηp2 = .503 after controlling for the effect of age (figure 5). However, bootstraps for 
parameter estimates revealed no significant differences in BPA or N100 distractor 
amplitude in determining non-AD or AD diagnosis. A binary logistic regression with 
Bias corrected and accelerated (BCa) bootstraps of BPA and N100 distractor amplitude 
also did not show significance.  
To examine whether group differences in N100 distractor amplitude between 
clinical groups matched the results of the NP battery, Spearman’s correlation was 
conducted (see appendix B for full table). NP results were converted into z-scores to 
allow for standardization of the different units of measurement. N100 distractor 
amplitude did not significantly correlate with NP battery performance. 
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Figure 5. Scatterplot shows distribution of N100 distractor amplitude among AD 
and non-AD groups. 
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DISCUSSION 
 
 The purpose of this study was to determine whether ERPs can be used as a 
biomarker of disease severity staging in AD within a heterogeneous group of patients 
presenting to a memory disorders clinic for initial evaluation. Our results, however 
limited, emphasizes the complex relationship between the neuroanatomical 
underpinnings of ERPs. Much work remains to be done to elucidate the clinical utility of 
ERPs. 
We hypothesized that in MCI due to AD, P3b would be abnormal. We did 
not obtain results that would either support or refute our hypothesis due to small 
sample size. Previous studies have found P3b with larger amplitude and 
significantly longer latency in patients with MCI due to AD who later progressed to 
dementia due to AD than healthy elderly controls (Golob, Irimajiri, & Starr, 2007). 
However, it is difficult to determine from previous literature whether P3b amplitude and 
latency would be significantly different between AD and non-AD groups since non-AD 
pathologies may alter brain regions or networks that coincide with AD pathology at MCI 
stage. 
For mild AD dementia, we hypothesized that P50, N100, P200, N200, and 
P300 would be abnormal. We found that N100 absolute amplitude to distractor 
tones was significantly increased in the AD group, which supported our hypothesis 
and suggested that sensory gating may be more impaired in mild AD dementia than 
in non-AD related cognitive impairments. The differences in our findings from those in 
the literature may be attributed to the fact that in this study, N100 amplitude is compared 
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to a non-AD group rather than healthy elderly controls as in other studies. The 
pathological changes unrelated to AD that may occur in outside the temporal lobe may 
still influence the generation of N100 signal. It has been suggested that ERP neural 
generators are engaged in a complex circuitry modulated by other structures where the 
loss of a neural generator may result in 1) the compensation of cognitive function by 
other brain regions, 2) loss of inhibitory or propagating mechanisms that the removed 
generator may have had on other ERP components and/or 3) the disruption of neuronal 
synchronicity or organization that may obfuscate ERP signals (Halgren et al., 1986, 
1998). This suggestion is supported by the observation of smaller N100 amplitudes in 
mild AD in comparison to healthy elderly controls (Cecchi et al., 2015, Golob et al., 
2007) but greater N100 amplitudes in MCI due to AD (Golob et al., 2007). 
For moderate to severe AD dementia, we hypothesized that P50, N100, P200, 
N200, and P300 components would be abnormal to an even greater extent than seen 
at mild AD dementia. We did not obtain results that would either support or refute 
our hypothesis, likely due to small sample size. It is difficult to predict the anticipated 
result since there are very few ERP studies that include data from patients at moderate to 
severe stages of AD dementia. Advanced stages of AD dementia profoundly affect 
function of higher cognition which may impede patients’ abilities to follow directions or 
perform tasks in research studies. Nevertheless, there is evidence from previous studies 
suggesting that we may not see longer latencies in N100 and P200 in AD compared to 
non-AD groups which is in contrary to our hypothesis. One study reported normal N100 
and P200 latencies during auditory task in an AD group that included severely impaired 
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patients (Goodin & Aminoff, 1986) and another found no significant differences in N100 
latency among patients who presented with a heterogeneous mixture of cognitive 
impairments (Goodin, Squires, & Starr, 1978). This line of evidence aligns with the 
histopathological observation that primary sensory cortices are often last to be affected by 
AD pathology. In fact, it seems unlikely to observe significant changes in N100 and P200 
latency between AD and non-AD groups given that primary sensory cortices are not often 
the direct cause of any cognitive impairment of known etiology. 
The interpretations of this study is limited to the comparison of 
predominantly mild AD to non-AD related cognitive impairment. The decision was 
made to consolidate the single patient with MCI due to AD with the eight mild AD 
dementia patients to account for as much as possible the small sample size. Previous 
studies have had mixed success using ERP to differentiate AD or conversion to AD from 
non-AD related disorders (Squires, Chippendale, Wrege, Goodin, & Starr, 1980; Gordon, 
Kraiuhin, Harris, Meares, & Hwson, 1986; Pfefferbaum, Wenegrat, Ford, Roth, & 
Kopell, 1984; Green et al., 2015). Evidence remains to be seen whether ERP is useful in 
the diagnosis of the clinical severity of AD from patients presenting with a heterogeneous 
etiologies of cognitive impairments. 
The non-AD group encompassed a wide number of etiologies for cognitive 
impairment, including neurodegenerative and non-neurodegenerative pathologies (figure 
6). A number of these disorders may disrupt brain structures or networks that generate the 
same ERP components as those disrupted in the different stages of AD. For example, 
frontotemporal dementia predominantly affects the frontal lobe which may alter ERP 
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components that may be generated by the region including the P50 and the P3a. 
However, possibility of multiple etiologies affecting the same ERP components only 
highlights the need to establish a pattern of abnormal ERP components specific to AD, 
much as it has been done with the NFT stages, beta-amyloid phases and 
neuropsychological batteries, to support, or even improve the accuracy of staging AD 
dementia. 
Figure 6. List of clinical diagnoses of participants in the non-AD group. Parentheses 
indicate the number of subjects that fell into each diagnosis.  
 
 
 
 
 
 
 
 
Furthermore, the results of this study must be taken with caution due to the 
lack of statistical power due to small sample size. Statistical power is the probability 
that a test will avoid committing a type II error. Low power may occur due to small 
sample sizes, small effect sizes, or both (Button et al., 2013). Low power leads to the 
overestimation of effect size and low reproducibility of the results. One simple method of 
avoiding this false positive inflation would be to increase the sample size. Although this 
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study attempts to control for small power by using the conservative Bonferroni post hoc 
tests whenever possible, larger sample sizes are needed to reduce potential type II errors. 
Conclusion 
The predictions of this study were driven by previous neuropathological results 
that show NFT and Aβ pathology disrupt specific neural regions or networks at different 
stages of AD, thus likely disrupting the ERP signals generated by these neuroanatomical 
structures. Our results indicate that N100 amplitude may be a promising discriminator of 
mild AD from non-AD related cognitive impairments. By comparing AD and non-AD 
groups, the current results of this study highlight the complex relationships between 
ERPs and their neural generators and their modulation by other regions. Ultimately, 
although it remains to be seen whether ERPs can successfully discriminate stages of AD 
within a heterogeneous group of patients presenting to a memory disorders clinic for 
initial evaluation, we do see promise of utilizing ERPs to deepen our understanding of the 
relationship between neuroanatomy and disease. 
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APPENDIX A 
 Rating form used by neurologists to evaluate ERP results.  
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